ATR 1072

July 14, 2026: Atrium Therapeutics, Inc. (NASDAQ: RNA) announced the FDA cleared its IND for ATR 1072, enabling initiation of the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome (a rare genetic, early-onset cardiomyopathy). Corventis is an open-label, multicenter study evaluating safety, tolerability, PK/PD, and efficacy, enrolling ~37 participants in two parts: Part A multiple ascending dose cohorts to support dose selection, and Part B a single-arm expansion at the recommended Phase 2 dose to assess safety and efficacy trends in cardiac structure and function. Site initiation is underway; the company expects first patient enrolled by end of 2026 and anticipates initial proof-of-concept data in 2H 2027. ATR 1072 is an siRNA designed to silence mutant PRKAG2 mRNA to normalize AMPK activity and reduce pathogenic cardiac glycogen accumulation. The release also notes a second precision cardiology candidate, ATR 1086, for PLN cardiomyopathy (no new milestone disclosed).